ethyl 3-oxo-2-(2-pyridylmethyl)butanoate | 3243-77-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: ethyl 3-oxo-2-(2-pyridylmethyl)butanoate
• 英文别名: 2-(2-Acetyl-2-ethoxycarbonyl-ethyl)-pyridin；2-(2-Picolyl)acetessigsaeure-ethylester；ethyl 2-(pyridin-2-yl-methyl)-3-oxobutanoate；3-oxo-2-pyridin-2-ylmethyl-butyric acid ethyl ester；ethyl 3-oxo-2-(pyridin-2-ylmethyl)butanoate
• CAS: 3243-77-4
• 化学式: C₁₂H₁₅NO₃
• 分子量: 221.256
• InChiKey: YFQDFFFAMVUQEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  56.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-oxo-2-(2-pyridylmethyl)butanoate 在 硫酸 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 生成 [4-methyl-2-oxo-3-(pyridin-2-ylmethyl)chromen-7-yl] N,N-dimethylcarbamate
  参考文献：
  名称：

  Discovery and structure–activity relationship of coumarin derivatives as TNF-α inhibitors

  摘要：

  The discovery and structure-activity relationship of a novel series of coumarin-based TNF-alpha inhibitors is described. Starting from the initial lead la, various derivatives were prepared surrounding the coumarin core structure to optimize the in vitro inhibitory activity of TNF-alpha production by human peripheral blood mononuclear cells (hPBMC), stimulated by bacterial lipopolysaccharide (LPS). Selected compounds also demonstrated in vivo inhibition of TNF-alpha production in rats. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.022
• 作为产物：
  描述：

  2-溴甲基吡啶 、 乙酰乙酸乙酯 在 potassium tert-butylate 作用下， 以 四氢呋喃 、 叔丁醇 为溶剂， 反应 0.5h， 以92%的产率得到ethyl 3-oxo-2-(2-pyridylmethyl)butanoate
  参考文献：
  名称：

  吡啶并[1,2-a]苯并咪唑类药物可有效对抗结核病 (TB)、耐多药 (MDR) 结核病和广泛耐药 (XDR) 结核病

  摘要：

  抗击结核病的斗争还远未结束。结核病由结核分枝杆菌引起，是全世界最致命的感染之一。人类免疫缺陷病毒（HIV）的合并感染以及耐多药结核病（MDR-TB）和广泛耐药结核病（XDR-TB）菌株的出现进一步加重了该病的负担。在此，我们报告了2-(4-氯苄基)-3-甲基-1-氧代-1 H ,5 H -吡啶并[1,2- a ]苯并咪唑-4-甲腈作为有效抗结核药物的发现及其结构该分子的修饰导致类似物具有更高的效力和更低的毒性。许多这些衍生物在亚微摩尔浓度下也具有对抗耐药结核菌株的活性，并且对 Vero 细胞没有明显的毒性，从而强调了它们作为开发新抗结核药物的新型支架的价值。

  DOI：

  10.1002/cmdc.201000490

文献信息

• [EN] 4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE 4H-[1,2,4]TRIAZOLO[5,1-B]PYRIMIDIN-7-ONE À TITRE D'ANTAGONISTES DES RÉCEPTEURS CCR2B
  申请人：ASTRAZENECA AB

  公开号：WO2011114148A1

  公开（公告）日：2011-09-22

  The present invention relates to novel compounds for use in the compositions, to processes for their preparation, to intermediates useful in their preparation and to their use as therapeutic agents. The present invention also relates to pharmaceutical compositions, which comprise compounds that act via antagonism of the CCR2b receptor for which MCP-1 is one of the known ligands and so may be used to treat inflammatory disease, atherosclerosis, diabetes, obesity, cancer, chronic obstructive pulmonary disease (COPD) rheumatoid arthritis and/or neuropathic pain, which is mediated by these receptors.

  本发明涉及用于组合物中的新化合物，用于它们的制备过程，用于它们的制备中有用的中间体以及它们作为治疗剂的用途。本发明还涉及包含通过对CCR2b受体的拮抗作用而起作用的化合物的药物组合物，其中MCP-1是已知的配体之一，因此可用于治疗由这些受体介导的炎症性疾病、动脉粥样硬化、糖尿病、肥胖症、癌症、慢性阻塞性肺病（COPD）、类风湿性关节炎和/或由这些受体介导的神经病痛。
• [EN] PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIMIDINE ET COMPOSITIONS ET MÉTHODES DE TRAITEMENT ASSOCIÉES
  申请人：AN2H DISCOVERY LTD

  公开号：WO2017210678A1

  公开（公告）日：2017-12-07

  The present disclosure is directed to pyrazolo[1,5-a]pyrimidine compounds of formula (I), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R21, R22, R23, R24 and R25 are as defined herein.

  本公开涉及式(I)的吡唑并[1,5-a]嘧啶化合物，其药物组合物以及调节或激活帕金连接酶的方法。本公开还涉及治疗和/或减少与帕金连接酶激活相关的疾病或病症的方法。R21、R22、R23、R24和R25如本文所定义。
• PYRAZOLOPYRIMIDINE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME
  申请人：An2H Discovery Limited

  公开号：US20200317674A1

  公开（公告）日：2020-10-08

  The present disclosure is directed to pyrazolo[1,5-a]pyrimidine compounds of formula (I), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R 21 , R 22 , R 23 , R 24 and R 25 are as defined herein.
• Discovery and structure–activity relationship of coumarin derivatives as TNF-α inhibitors
  作者：Jie-Fei Cheng、Mi Chen、David Wallace、Sovouthy Tith、Thomas Arrhenius、Hirotaka Kashiwagi、Yoshiyuki Ono、Akira Ishikawa、Haruhiko Sato、Toshiro Kozono、Hediki Sato、Alex M. Nadzan

  DOI：10.1016/j.bmcl.2004.03.022

  日期：2004.5

  The discovery and structure-activity relationship of a novel series of coumarin-based TNF-alpha inhibitors is described. Starting from the initial lead la, various derivatives were prepared surrounding the coumarin core structure to optimize the in vitro inhibitory activity of TNF-alpha production by human peripheral blood mononuclear cells (hPBMC), stimulated by bacterial lipopolysaccharide (LPS). Selected compounds also demonstrated in vivo inhibition of TNF-alpha production in rats. (C) 2004 Elsevier Ltd. All rights reserved.
• Pyrido[1,2-<i>a</i>]benzimidazole-Based Agents Active Against Tuberculosis (TB), Multidrug-Resistant (MDR) TB and Extensively Drug-Resistant (XDR) TB
  作者：Marco Pieroni、Suresh K. Tipparaju、Shichun Lun、Yang Song、A. Willem Sturm、William R. Bishai、Alan P. Kozikowski

  DOI：10.1002/cmdc.201000490

  日期：2011.2.7

  The struggle against tuberculosis (TB) is still far from over. TB, caused by Mycobacterium tuberculosis, is one of the deadliest infections worldwide. Co‐infection with human immunodeficiency virus (HIV) and the emergence of multidrug‐resistant tuberculosis (MDR‐TB) and extensively drug‐resistant tuberculosis (XDR‐TB) strains have further increased the burden for this disease. Herein, we report the

  抗击结核病的斗争还远未结束。结核病由结核分枝杆菌引起，是全世界最致命的感染之一。人类免疫缺陷病毒（HIV）的合并感染以及耐多药结核病（MDR-TB）和广泛耐药结核病（XDR-TB）菌株的出现进一步加重了该病的负担。在此，我们报告了2-(4-氯苄基)-3-甲基-1-氧代-1 H ,5 H -吡啶并[1,2- a ]苯并咪唑-4-甲腈作为有效抗结核药物的发现及其结构该分子的修饰导致类似物具有更高的效力和更低的毒性。许多这些衍生物在亚微摩尔浓度下也具有对抗耐药结核菌株的活性，并且对 Vero 细胞没有明显的毒性，从而强调了它们作为开发新抗结核药物的新型支架的价值。